Skip to content
 +33 (0)5 35 54 19 36       contact@matwin.fr
FacebookTwitterYouTubeLinkedIn
Matwin Logo Matwin Logo Matwin Logo
  • HOME
  • WHO ARE WE ?
    • MATWIN’s platform
    • Our partners
    • MATWIN International Board
    • The team
  • OUR ACTIONS
    • Accelerating programme
    • Tailor made service offers
    • MEET2WIN
    • OncoSTART
  • CALLS FOR APPLICATION
    • MATWIN’s Call for applications
    • Projects & candidates supported by MATWIN
    • Other calls for application
  • NEWS
    • News
    • Agenda
    • Press
  • CONTACT
  • Français
  • English
  • HOME
  • WHO ARE WE ?
    • MATWIN’s platform
    • Our partners
    • MATWIN International Board
    • The team
  • OUR ACTIONS
    • Accelerating programme
    • Tailor made service offers
    • MEET2WIN
    • OncoSTART
  • CALLS FOR APPLICATION
    • MATWIN’s Call for applications
    • Projects & candidates supported by MATWIN
    • Other calls for application
  • NEWS
    • News
    • Agenda
    • Press
  • CONTACT
  • Français
  • English
  • HOME
  • WHO ARE WE ?
    • MATWIN’s platform
    • Our partners
    • MATWIN International Board
    • The team
  • OUR ACTIONS
    • Accelerating programme
    • Tailor made service offers
    • MEET2WIN
    • OncoSTART
  • CALLS FOR APPLICATION
    • MATWIN’s Call for applications
    • Projects & candidates supported by MATWIN
    • Other calls for application
  • NEWS
    • News
    • Agenda
    • Press
  • CONTACT
  • Français
  • English

MATWIN ANNUAL REPORT 2019

stephanie.dhont2020-05-06T09:56:59+02:00

Partagez cette histoire, choisissez votre plate-forme !

FacebookTwitterRedditLinkedInTumblrPinterest

Related Posts

BIPER THERAPEUTICS RAISES €1.25 MILLION
BIPER THERAPEUTICS RAISES €1.25 MILLION

BIPER THERAPEUTICS RAISES €1.25 MILLION

Partnership MATWIN and European Health Investor Network
Partnership MATWIN and European Health Investor Network

Partnership MATWIN and European Health Investor Network

Genoscience Pharma receives FDA orphan drug designation for ezurpimtrostat to treat hepatocellular carcinoma
Genoscience Pharma receives FDA orphan drug designation for ezurpimtrostat to treat hepatocellular carcinoma

Genoscience Pharma receives FDA orphan drug designation for ezurpimtrostat to treat hepatocellular carcinoma

First US leukemia patient dosed with investigational SMART101 cell therapy
First US leukemia patient dosed with investigational SMART101 cell therapy

First US leukemia patient dosed with investigational SMART101 cell therapy

Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”
Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”

Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”

Categories

  • Call for application (39)
  • Diary (11)
  • News (27)
  • Non classé (1)
  • Press (12)

Follow us

MATWIN Copyright 2017 | All Rights Reserved | Powered by Argonautt | Imprint
FacebookTwitterYouTubeLinkedIn
Page load link
Go to Top